WO2012058666A3 - Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy - Google Patents

Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy Download PDF

Info

Publication number
WO2012058666A3
WO2012058666A3 PCT/US2011/058558 US2011058558W WO2012058666A3 WO 2012058666 A3 WO2012058666 A3 WO 2012058666A3 US 2011058558 W US2011058558 W US 2011058558W WO 2012058666 A3 WO2012058666 A3 WO 2012058666A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
water
compound
cancer therapy
Prior art date
Application number
PCT/US2011/058558
Other languages
French (fr)
Other versions
WO2012058666A2 (en
Inventor
Fengzhi Li
Xiang Ling
Shousong Cao
Original Assignee
Health Research, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US40799610P priority Critical
Priority to US61/407,996 priority
Application filed by Health Research, Inc. filed Critical Health Research, Inc.
Publication of WO2012058666A2 publication Critical patent/WO2012058666A2/en
Publication of WO2012058666A3 publication Critical patent/WO2012058666A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof

Abstract

Provided are compositions, methods of making the compositions, and methods of using the compositions. The compositions can be provided as pharmaceutical preparations for use in disease treatment, such as cancer therapy. The compositions include novel pharmaceutical preparations which contain effective concentrations of a chemical compound. One compound used is 10H-1,3-Dioxolo[4,5-g]pyrano[3',4':6,7]indolizino[1,2-b] quinoline-8,11(7H,12H)-dione, 7-ethyl-7- hydroxy-, (S)-. The invention also provides methodologies for preparing pharmaceutical preparations for use in intravenous and oral pharmaceutical preparations that contain drug compounds that are difficult to dissolve in water.
PCT/US2011/058558 2010-10-29 2011-10-31 Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy WO2012058666A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US40799610P true 2010-10-29 2010-10-29
US61/407,996 2010-10-29

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13/881,785 US9422303B2 (en) 2010-10-29 2011-10-31 Formulations of water-insoluble chemical compounds and methods of using a formulation of compound FL118 for cancer therapy
CA2816418A CA2816418A1 (en) 2010-10-29 2011-10-31 Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy
EP11837250.7A EP2632264B1 (en) 2010-10-29 2011-10-31 Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy
CN201180063530.5A CN103442565B (en) 2010-10-29 2011-10-31 Compound fl118 formulations for the treatment of cancer and method of preparation of novel water-insoluble compound

Publications (2)

Publication Number Publication Date
WO2012058666A2 WO2012058666A2 (en) 2012-05-03
WO2012058666A3 true WO2012058666A3 (en) 2013-01-10

Family

ID=45994848

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/058558 WO2012058666A2 (en) 2010-10-29 2011-10-31 Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy

Country Status (5)

Country Link
US (1) US9422303B2 (en)
EP (1) EP2632264B1 (en)
CN (1) CN103442565B (en)
CA (1) CA2816418A1 (en)
WO (1) WO2012058666A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106715443A (en) * 2014-03-26 2017-05-24 坎格特生物技术制药有限责任公司 Use of the FL118 core chemical structure platform to generate FL118 derivatives for treatment of human disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0556585A2 (en) * 1992-01-24 1993-08-25 Takeda Chemical Industries, Ltd. Condensed camptothecin derivatives their production and use as antitumor agents
US6653319B1 (en) * 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340817A (en) 1987-04-14 1994-08-23 Research Triangle Institute Method of treating tumors with anti-tumor effective camptothecin compounds
WO2001074401A2 (en) * 2000-03-31 2001-10-11 Supergen, Inc. Camptothecin complexes
CA2412790C (en) * 2000-06-30 2012-11-06 Inex Pharmaceuticals Corporation Liposomal antineoplastic drugs and uses thereof
US6509027B2 (en) * 2001-02-12 2003-01-21 Supergen, Inc. Injectable pharmaceutical composition comprising coated particles of camptothecin
WO2008073201A2 (en) 2006-11-10 2008-06-19 Health Research Inc. Compositions and methods for identifying agents that alter expression of survivin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0556585A2 (en) * 1992-01-24 1993-08-25 Takeda Chemical Industries, Ltd. Condensed camptothecin derivatives their production and use as antitumor agents
US6653319B1 (en) * 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE PUBCHEM [online] 27 March 2005 (2005-03-27), XP003031894, retrieved from NCBI Database accession no. CID 437971 *
See also references of EP2632264A4 *

Also Published As

Publication number Publication date
EP2632264B1 (en) 2019-10-02
US20140066470A1 (en) 2014-03-06
WO2012058666A2 (en) 2012-05-03
CN103442565B (en) 2016-08-10
US9422303B2 (en) 2016-08-23
CA2816418A1 (en) 2012-05-03
CN103442565A (en) 2013-12-11
EP2632264A4 (en) 2014-04-23
EP2632264A2 (en) 2013-09-04

Similar Documents

Publication Publication Date Title
JO3265B1 (en) Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease
MX2007000883A (en) Insulin-oligomer conjugates, formulations and uses thereof.
WO2009007751A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
WO2013158680A3 (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
IL217044A (en) Derivatives of 5h-[1,3]thiazolo[3,2-a]pyrimidin-5-one or pharmaceutically acceptable salts thereof, pharmaceutical compositions containing same, a method of modulating activity of pi3k kinase using same and use thereof
UA99141C2 (en) Substituted indazole derivatives active as kinase inhibitors
IL170970A (en) Nitroimidazolyl alkyl protected antineoplastic agents and their use in the preparation of anticancer medicaments
EA201000092A1 (en) Triple-substituted pyrimidine derivatives for the treatment of proliferative diseases
EA201291348A1 (en) Activators of soluble guanylatzyclases
EA200901277A1 (en) Pharmaceutical compositions containing dapaglyflosine propylene glycolhydrate
IL201977A (en) 6-(pyrrolidin-3-yl)-pyrazolo[3,4-d]pyrimidin-4-ones, pharmaceutical compositions comprising them and their use in the preparation of medicaments for the treatment of diseases
WO2007134292A3 (en) Treprostinil administration using a metered dose inhaler
IL227087D0 (en) (2s,5r)-6-(benzyloxy/allyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylates, process for their preparation and use of (2s,5r)-tert-butyl-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylate for preparing anti-infective medicaments
NZ621433A (en) Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
WO2012118812A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
NZ600430A (en) Spiro-oxindole mdm2 antagonists
IL214033D0 (en) 3h-imidazo[4,5-c]pyridine-6-caboxamides as anti-inflammatory agents
TW200638935A (en) Pyridazine derivatives and their use as therapeutic agents
NZ566705A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
WO2009094668A8 (en) New 2,3,4,5-tetrahydro-1h-pyrido[ 4,3-b] indole compounds and methods of use thereof
NZ563774A (en) Inhibitors of VEGF receptor and HGF receptor signaling
WO2010032140A3 (en) Pharmaceutical compositions and related methods of delivery
EA201490647A1 (en) Derivatives of benzothiazol-6-lucus acid and their application for the treatment of hiv infection
WO2006107771A3 (en) PYRAZOLO[3,4-c]QUINOLINES, PYRAZOLO[3,4-c]NAPHTHYRIDINES, ANALOGS THEREOF, AND METHODS
NZ599815A (en) N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11837250

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase in:

Ref document number: 2816418

Country of ref document: CA

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011837250

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13881785

Country of ref document: US